IP Library Granted Patent US 7,141,434
Granted Patent B2
US 7,141,434 · App. 10/197,381 · Granted Nov 28, 2006

Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing an adenosine kinase

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,141,434
App. No.
10/197,381
Granted
Nov 28, 2006
Kind
B2
Abstract

The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize an adenosine kinase as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.

Claims (27)

1. A method of identifying a compound that modulates IL-4 receptor-mediated IgE production, comprising determining whether the compound binds an adenosine kinase, wherein the ability to bind the adenosine kinase identifies the compound as being a modulator of IL-4 induced IgB production.

2. The method of claim 1 in which the compound identified inhibits IL-4 receptor-mediated IgB production.

3. The method of claim 1 in which the compound identified inhibits IL-4 receptor-mediated isotype switching of B-cells.

4. The method of claim 1 in which the compound identified inhibits IL-4 induced transcription of a germ line ε promoter.

5. The method of claim 1 in which the compound specifically modulates IL-4 induced IgE production without significantly modulating production of another Ig isotype.

6. The method of claim 1 in which the adenosine kinase is a mammalian adenosine kinase.

7. The method of claim 6 in which the adenosine kinase is a human adenosine kinase.

8. The method of claim 1 in which it is determined whether the compound binds the adenosine kinase in a competitive binding assay.

9. The method of claim 8 in which the compound competes for binding the adenosine kinase with an active AR02E8 compound.

10. The method of claim 9 in which the active AR02E8 compound is selected from the group consisting of AR02E8wt (SEQ ID NO:1), AR02E8VC (SEQ ID NO2), AR02E8RS (SEQ ID NO:3) and a peptide analog thereof in which one or more of the amide linkages are replaced with an isostere of an amide.

11. The method of claim 1 which is carried out in a cell-free system with an isolated adenosine kinase.

12. The method of claim 1 in which the compound is a small organic compound.

13. The method of claim 12 in which the small organic compound has a molecular weight in the range of about 100–2500 dalton.

14. The method of claim 1 in which the compound is selected from the group consisting of peptides and peptide isosteres.

15. The method of claim 1 , further including the step of confirming that the identified compound modulates IL-4 induced IgE production .

16. A method of identifying compounds that modulate IL-4 receptor-mediated IgB production, comprising the step of contacting a compound from pool of candidate compounds with an adenosine kinase and identifying those compounds of the pool that bind the adenosine kinase, thereby identifying those compounds of the pool that modulate IL-4 receptor mediated IgB production.

17. The method of claim 16 which is carried out in the presence of a compound known to bind the adenosine kinase such that those compounds of the pool that competitively bind the adenosine kinase are identified.

18. The method of claim 17 in which the compound known to bind the adenosine kinase is an active AR02E8 compound.

19. The method of claim 18 in which the active AR02E8 compound is selected from the group consisting of AR02E8wt (SEQ ID NO:1), AR02E8VC (SEQ ID NO2), AR02E8RS (SEQ ID NO:3) and a peptide analog thereof in which one or more of the amide linkages are replaced with an isostere of an amide.

20. The method of claim 16 in which the candidate compounds are peptides or small organic compounds.

21. The method of claim 20 in which the pool of candidate compounds is a phage display library.

22. The method of claim 20 in which the candidate compounds are immobilized on a substrate or a plurality of substrates.

23. The method of claim 16 in which the compound or adenosine kinase is labeled with a detectable label.

24. The method of claim 16 in which the adenosine kinase is immobilized on a substrate.

25. The method according to claim 1 or claim 16 in which the adenosine kinase is a polypeptide having an amino acid sequence selected from the group consisting of the sequence of SEQ ID NO:12 and the sequence of SEQ LID NO:13.

26. A kit for identifying compounds that modulate IL-4 induced IgB production, comprising an adenosine kinase or a cell expressing an adenosine kinase and an active AR02E8 compound.

27. The kit of claim 26 in which the active AR02E8 compound is selected from the group consisting of AR02E8wt (SEQ ID NO: 1), AR02E8VC (SEQ ID N02), AR02E8RS (SEQ ID NO:3) and a peptide analog thereof in which one or more of the amide linkages are replaced with an isostere of an amide.

Assignments (2)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2002
From: MASUDA, ESTEBAN; KINSELLA, TODD M.; WARNER, JUSTIN E.; KINOSHITA, TAISEI; BENNETT, MARK K.; ANDERSON, DAVID C.
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 013393/0869 →